Elanco

ELANPhase 3

Greenfield, United StatesFounded 1954elanco.com

Elanco Animal Health, spun off from Eli Lilly in 2018, is one of the world's largest animal health companies serving veterinarians, pet owners, and farmers globally. The company's diverse portfolio includes vaccines, parasiticides, antibiotics, and other therapeutics for both companion animals and food-producing animals. With significant R&D investments and strategic acquisitions including Bayer Animal Health, Elanco continues to expand its market leadership in the growing animal health sector.

Market Cap

$11.9B

Founded

1954

Employees

9,000-11,000

Focus

Biotech

ELAN · Stock Price

USD 23.982.61 (-9.82%)

Historical price data

AI Company Overview

Technology Platform

Elanco develops and manufactures a comprehensive portfolio of animal health products including vaccines, parasiticides, antibiotics, and nutritional supplements for both companion animals and livestock through advanced biologics, small molecule chemistry, and digital health platforms.

Pipeline Snapshot

14 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
zonisamide	Bipolar Disorders	Approved
cefepime + ceftriaxone	Pneumonia	Approved
tizanidine hydrochloride capsule	Multiple Sclerosis	Phase 3
Ziconotide	Pain	Phase 3
Prialt (ziconotide)	Pain	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 2018

Opportunities

Elanco is positioned to capitalize on the growing global animal health market driven by increasing pet ownership, rising demand for animal protein, and expanding presence in emerging markets.

The company's recent acquisitions and R&D investments provide significant growth potential.

Risk Factors

Key risks include regulatory pressures on antibiotic use in animals, generic competition as patents expire, economic sensitivity affecting pet and livestock spending, and execution challenges from large acquisitions requiring successful integration.

Competitive Landscape

Elanco competes in a consolidated animal health market dominated by Zoetis, Merck Animal Health, and Boehringer Ingelheim. The company differentiates through its broad product portfolio, global distribution network, and strong veterinary relationships following strategic acquisitions.

Publications

Patents

Pipeline